Immunome
IMNM
142 hedge funds and large institutions have $518M invested in Immunome in 2025 Q1 according to their latest regulatory filings, with 39 funds opening new positions, 71 increasing their positions, 16 reducing their positions, and 17 closing their positions.
344% more repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 16
129% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 17
18% more funds holding
Funds holding: 120 → 142 (+22)
3.08% more ownership
Funds ownership: 85.41% → 88.49% (+3.1%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
8% less capital invested
Capital invested by funds: $566M → $518M (-$47.9M)
98% less call options, than puts
Call options by funds: $449K | Put options by funds: $29.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$35.2M |
| 2 |
Primecap Management
Pasadena,
California
|
+$30.1M |
| 3 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$19.7M |
| 4 |
BlackRock
New York
|
+$14.8M |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$14.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$13.1M |
| 2 |
Renaissance Technologies
New York
|
-$1.92M |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$1.14M |
| 4 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$902K |
| 5 |
Goldman Sachs
New York
|
-$772K |
IMNM Hedge Fund Activity: Q1 2025 in Review
142 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Immunome (IMNM) for Q1 2025, worth a combined $518M — down 8.5% from $566M a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new IMNM positions and 17 closed out — a net gain of 22 holders — while 71 added to existing stakes and 16 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $35.2M. The largest seller was Janus Henderson Group, cutting an estimated $13.1M.
- 142 institutional investors held Immunome (IMNM) as of Q1 2025, up from 120 in Q4 2024.
- Funds reported $518M of Immunome stock for Q1 2025, down 8.5% quarter-over-quarter.
- 39 funds opened new Immunome positions in Q1 2025 and 17 closed out, a net change of +22 holders.
- The largest Immunome buyer in Q1 2025 was Point72 Asset Management, an estimated $35.2M added.
- The largest Immunome seller in Q1 2025 was Janus Henderson Group, an estimated $13.1M sold.
Based on aggregated 13F filings for Q1 2025.